Loading...
Market
How will Johnson & Johnson's new bispecific immunology medications perform in the market two years after launch?
4
Resolution / Starting Odds
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
sales data and market analysis reports
Story
Johnson & Johnson to Acquire Proteologix for $850 Million, Including Dual-Targeting Antibody Drugs
May 16, 2024, 12:25 PM
Johnson & Johnson announced on Thursday that it will acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment. The acquisition aims to bolster Johnson & Johnson's leadership in the treatment of atopic dermatitis. Proteologix brings a young roster of bispecific immunology medications, including a phase 1-ready asset targeting TSLP and dual-targeting antibody drugs. The acquisition has seen Johnson & Johnson's stock (JNJ) rise by 0.1% in pre-market trading.
View original story
Similar markets
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock Price Increases • 33%
Stock Price Decreases • 33%
Stock Price Remains Stable • 34%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened financial performance • 25%
Exceed $500 million • 25%
Between $300 million and $500 million • 25%
Between $100 million and $300 million • 25%
Below $100 million • 25%
Above $5 billion • 25%
Between $3 billion and $5 billion • 25%
Between $1 billion and $3 billion • 25%
Below $1 billion • 25%
Launch new competing drug • 33%
Enhance marketing of existing drugs • 33%
No significant response • 34%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Becomes market leader in obesity drugs • 30%
Performs moderately without leading the market • 30%
Underperforms compared to existing treatments • 40%